DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



SAM-e for the Treatment of Depression in Patients With Parkinson's Disease

Information source: New York University School of Medicine
ClinicalTrials.gov processed this data on August 20, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Parkinson's Disease; Depression

Intervention: SAM-e (Drug); oral citalopram (Drug); placebo (Drug)

Phase: Phase 2/Phase 3

Status: Completed

Sponsored by: New York University School of Medicine

Official(s) and/or principal investigator(s):
Alessandro Di Rocco, MD, Principal Investigator, Affiliation: NYU

Summary

This study will test a chemical called s-adenosyl-methionine (SAM-e) for the treatment of depression in patients with Parkinson's disease (PD).

Clinical Details

Official title: SAM-e Treatment of Depression in Parkinson's Disease

Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment

Primary outcome: Change in Hamilton Depression Scale

Detailed description: PD is commonly associated with depression, but conventional antidepressants have limited efficacy in patients with PD and may exacerbate motor symptoms. SAM-e is available in the United States as a food supplement and is promoted as a mood enhancer. SAM-e improves dopamine transmission, may have a beneficial effect on dopamine receptors, and may be a good alternative to the currently-used antidepressants in patients with PD. This study will investigate whether SAM-e is safe and effective in the treatment of depression associated with PD. The efficacy of SAM-e will be compared to placebo and to escitalopram, a selective serotonin reuptake inhibitor commonly used for the treatment of depression in PD. Participants in this study will be randomly assigned to receive SAM-e, escitalopram, or placebo for 12 weeks. Some participants may choose to extend treatment for an additional 12 weeks (for a total of 24 weeks on study medication). Participants will have study visits at entry and Weeks 2, 4, 8, and 12. Study visits will include neurological evaluation, psychiatric evaluation, blood tests, and quality of life questionnaires. A telephone interview will be conducted at Week 10.

Eligibility

Minimum age: 30 Years. Maximum age: 80 Years. Gender(s): Both.

Criteria:

Inclusion Criteria

- Idiopathic Parkinson's disease as indicated by the presence of at least two of the

following signs: resting tremor, rigidity, bradykinesia, or postural reflex impairment

- Stable anti-parkinson medication regimen, with no change in medications in the 4

weeks prior to study entry

- No antidepressant or antipsychotic medications within 30 days prior to study entry

- Agree not to start other pharmacotherapy, psychotherapy, or behavior therapy while

participating in the trial

- Acceptable methods of contraception

- Ability to read and/or follow written and oral instructions presented in English

- Sufficient cognitive ability (baseline Mini-Mental Status > 24) to provide informed

consent Exclusion Criteria

- History of cardiac, hepatic, renal, hematologic, respiratory, endocrine, vascular,

metabolic, or other systems abnormalities that are clinically relevant in the opinion of study officials

- Certain abnormal laboratory values

- Pregnant or breastfeeding

- Use of an investigational drug within 3 months of study entry

- Use of St. John's Wort or any other "natural" product known to have mood enhancing

properties in the 30 days prior to study entry

- Selegiline or other monoamine oxidase inhibitor within the 6 weeks prior to study

entry

- Regular usage of anti-anxiety medications or habitual use of sleep medications,

although occasional use of certain hypnotics (temazepam, melatonin, or zolpidem) is allowed

- Psychotherapy initiated in the 6 months prior to study entry

- History of bipolar disorder, hypomania, mania, schizophrenia, or other psychotic

disorder

- Serious suicidal attempt in the 12 months prior to study entry or serious suicidal

tendencies/potential

- Use of dopamine receptor antagonist (metoclopramide, haloperidol)

- Secondary Parkinsonian symptoms due to drugs (including dopamine receptor

antagonists), metabolic disorders, cerebrovascular disease, encephalitis, or other degenerative diseases

Locations and Contacts

New York University, New York, New York 10003, United States
Additional Information

Starting date: July 2003
Last updated: January 17, 2013

Page last updated: August 20, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017